Top News

Novartis will acquire assets associated with Takeda Pharmaceuticals’ Xiidra (lifitegrast ophthalmic solution) 5%, an eye-care drug.

Sandoz’s new CEO will assume responsibilities no later than Aug. 1, 2019.

Catalent’s acquisition of Paragon Bioservices will provide expertise in expanding gene therapy market.

Shareholders have approved the issuance of Bristol-Myers Squibb common stock for the pending $74-billion merger with Celgene.

With the spin-off, Alcon will operate as a standalone company, and Novartis will focus on its core innovative medicines.

Amgen issued a notice of termination of its migraine collaboration agreements with Novartis, against which Novartis filed a lawsuit in response.

A $1.7-billion acquisition CDMO Brammer Bio establishes Thermo Fisher Scientific in viral vector manufacturing.

Richard Francis will step down as CEO of Sandoz, effective March 31, 2019.

Norman (Ned) Sharpless, director of the National Cancer Institute at the National Institutes of Health, will become FDA acting commissioner.

Ned Sharpless is tapped to take on acting commissioner role following Gottlieb’s resignation.

The acquisition of the site in Copenhagen, Denmark, will significantly expand Fujifilm’s capacity and capabilities.

FDA Commissioner Gottlieb released a statement on the agency’s efforts to refine the naming convention for biosimilars to balance competition and to help ensure patient safety.

The acquisition will establish a clinical pipeline for Biogen of gene-therapy candidates in ophthalmology.

The FDA commissioner plans to leave the agency in April.

The $4.3-billion acquisition is expected to strengthen Roche’s gene therapy pipeline.

The $21.4-billion acquisition will create stand-alone business within Danaher’s life-sciences portfolio.

FDA came away with the largest boost in its annual budget in a decade as part of the final spending package approved by Congress this week.

The companies will jointly develop and commercialize an investigational bifunctional fusion protein immunotherapy currently in clinical development for cancer treatment.

Supply chain players are eligible to participate in FDA’s pilot program to develop an electronic system for tracking drug products.

Janssen and MeiraGTx will collaborate on the development and commercialization of gene therapies for treating inherited retinal diseases.

Company to focus on innovation, growth, and productivity with creation of new units.

The acquisition of biopharmaceutical company TESARO is expected to strengthen GSK’s oncology pipeline and commercial footprint.

The $8-billion acquisition will broaden Lilly's oncology portfolio in precision medicines and treatments that target cancers caused by specific gene abnormalities.

Merger cites combined strengths in oncology, immunology and inflammation, and cardiovascular disease.

Core functions and those funded by fiscal year 2018 user fees are continuing, and 59% of the agency’s staffers are being retained.

The proposed $12.7-billion deal includes the spinoff of GSK and Pfizer consumer brands to a new UK-listed company.

The $62-billion acquisition of Shire by Takeda Pharmaceutical was approved by both sets of shareholders.

FDA cites Zhejiang Huahai Pharmaceutical in valsartan impurity investigation.